Gain Therapeutics, Inc.
GANX
$1.71
-$0.04-2.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.81M | -4.53M | -3.77M | -4.49M | -8.14M |
| Total Depreciation and Amortization | 9.30K | 9.70K | 9.30K | 9.60K | 9.60K |
| Total Amortization of Deferred Charges | 13.00K | 11.00K | 12.00K | 12.00K | 11.00K |
| Total Other Non-Cash Items | 1.20M | 529.10K | 913.30K | 313.30K | 1.32M |
| Change in Net Operating Assets | -507.50K | 158.80K | -621.00K | -1.93M | 1.05M |
| Cash from Operations | -5.10M | -3.82M | -3.45M | -6.08M | -5.76M |
| Capital Expenditure | -- | -- | -900.00 | 0.00 | -21.50K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -42.50K | 0.00 | 2.02M |
| Cash from Investing | -- | -- | -43.40K | 0.00 | 2.00M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -24.20K | -22.20K | -22.80K | -23.10K | -22.10K |
| Issuance of Common Stock | 2.49M | 2.42M | 2.34M | 831.80K | 10.06M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 0.00 | 0.00 | 0.00 |
| Cash from Financing | 2.47M | 2.40M | 2.31M | 808.70K | 10.04M |
| Foreign Exchange rate Adjustments | 260.10K | 109.50K | -480.60K | 382.80K | 13.10K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.37M | -1.31M | -1.67M | -4.88M | 6.30M |